Compare Enbridge Inc (ENB) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Enbridge Inc trades at $47.45 (market cap $105.81B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Enbridge Inc is far larger — about 12.5× Hinge Health Inc. Class A Common Stock's market cap, and Enbridge Inc pays a 5.91% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| ENB | HNGE | |
|---|---|---|
Market Cap | $105.81B | $8.47B |
Volume | 3,872,535 | 1,624,526 |
Sector | Energy | Health |
52-Week High | $58.04 | $105.14 |
52-Week Low | $45.23 | $31.17 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $188.05B | $8.09B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $47.46, up 1.09% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly earnings beats. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%. Analyst consensus is split between Buy and Hold, with a $61.63 price target suggesting significant upside. The stock offers a 6% dividend yield, supported by stable cash flows from its midstream energy operations.
Outlook is mixed: robust EBITDA growth and strategic expansion into renewables provide long-term value, but rising debt levels and interest rate sensitivity pose risks. Near-term performance may hinge on Q3 2026 earnings versus the $0.38 estimate. Institutional interest remains strong, as seen in Nykredit's $51.75M purchase in September 2026.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
